Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 2.

Table 2 Mean pharmacokinetic parameters (± standard deviation) of tofacitinib after its oral administration at a dose of 20 mg/kg to CON, LGN, AKI, and AKI-LGN rats

Parameters CON (n=5) LGN (n=5) AKI (n=6) AKI-LGN (n=7)
Body weight (g) 257 ± 10.1 251 ± 5.29 195 ± 2.40* 223 ± 14.7
AUC (µg∙min/mL) 215 ± 27.4 277 ± 33.1 571 ± 124* 289 ± 33.3
Cmax (µg/mL) 1.98 ± 0.712 4.03 ± 2.06 2.09 ± 0.525 2.52 ± 0.886
Tmax (min) 30.0 ± 10.6 16.0 ± 8.94 75.0 ± 48.4 39.3 ± 28.8
CLR (mL/min/kg) 11.7 ± 1.40 7.21 ± 0.950 0.610 ± 0.361* 5.30 ± 0.733
Ae0-24 h (% of dose) 12.4 ± 0.833 9.95 ± 1.36 1.66 ± 0.836* 7.69 ± 1.55
GI24 h (% of dose) 0.256 ± 0.162 0.120 ± 0.0821 0.859 ± 0.497 0.463 ± 0.142
F (%) 44.2 45.7 43.7 58.0

Ae0-24 h, the drug excreted as an unchanged form in the urine for 24 h; AKI, acute kidney injury; AKI-LGN, acute kedney injury-logaini; AUC, area under plasma concentration-time curves from time zero to time infinity; Cmax, maximum plasma concentration; CLR, time-averaged renal clearance; CON, control; F, absolute oral bioavailability; GI24 h, the percentage of drug remaining in the gastrointestinal tract at 24 h; LGN, loganin; Tmax, time to reach Cmax. *AKI is significantly different (p<0.05) from CON, LGN and AKI-LGN.
Biomolecules & Therapeutics 2024;32:601~610 https://doi.org/10.4062/biomolther.2024.008
© Biomolecules & Therapeutics